Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Mobility · older people living in the community with frailty
1 finding from 1 review
Level of functioning · older people living in the community with frailty
2 findings from 1 review
Mobility · older people living in the community with frailty
2 findings from 1 review
Level of functioning · older people living in the community with frailty
1 finding from 1 review
Mobility · older people living in the community with frailty
1 finding from 1 review
Level of functioning · older people living in the community with frailty
1 finding from 1 review
PROMs (long term) Measurements: SMFA (range 0–100, higher values indicate worse function) KSS (range 0–100, where higher values indicate better function) · adults with fractures of the distal femur
1 finding from 1 review
QoL · adults with fractures of the distal femur
2 findings from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Oerlemans 1999 Disability as measured by the impairment level sum score (5 to 50) Higher scores indicate greater impairment Measured 12 months post recruitment · adults with CRPS I
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review
Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
Laser therapy may leads to higher scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment ‐… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.96 [1.11, 3.45]
Studies not reported
Low
Scar severity ‐ Fractional CO2 Laser versus no treatment ‐ VBS (higher scores = worse scar appearance) ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) ‐ Vancouver Burn Scar (VBS) (Higher score = worse scar appearance) ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
2 findings from 1 review
no estimate extracted
Studies not reported
Very low
no estimate extracted
Studies not reported
Very low
Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) ‐ Vancouver Burn Scar (VBS) (Higher score = worse scar appearance) ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low